Article info

other Versions

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab

Authors

  1. Correspondence to Dr Rebecca Kristeleit, Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK; rebecca.kristeleit{at}gstt.nhs.uk
View Full Text

Citation

Kristeleit R, Mathews C, Redondo A, et al
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab

Publication history

  • Received February 25, 2022
  • Accepted July 5, 2022
  • First published August 16, 2022.

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.